##  [What is Japanese Clinical Data Comparability?](/index%2ephp/what-is-japanese-clinical-data-comparability) 

1 min read 

 Your browser does not support the audio element.





**Japanese clinical data comparability** refers to the process of showing that the safety and effectiveness of a drug — proven in non-Japanese patients (often Caucasian) — is also true for Japanese patients.

Japan’s **Pharmaceuticals and Medical Devices Agency (PMDA)** requires this because ethnic differences — such as genetics, body composition, diet, or metabolism — can affect how a drug works. Data from Western clinical trials may not always apply directly to Japanese patients.

To confirm comparability, companies may:

- Conduct **bridging studies** in Japanese patients
- Include Japanese participants in **global multi-regional clinical trials (MRCTs)**
- Perform **PK/PD studies** to check absorption and drug processing

This ensures the treatment is safe and effective for Japanese patients before approval.

**Why it matters:** Without demonstrating comparability, PMDA approval can be delayed, leading to extra studies and higher costs.

## How Freyr Solutions helps:

Freyr’s **Japan-based experts** guide companies in:

- Reviewing existing foreign data for gaps
- Designing and managing local Japanese studies
- Preparing PMDA-compliant documentation
- Engaging with the PMDA early to avoid roadblocks

f you’re bringing your product to Japan, let Freyr Solutions help you bridge the gap with expert clinical data comparability strategies. Contact us today.